Oncotelic Therapeutics Shares Outstanding 2006-2021 | OTLC

Oncotelic Therapeutics shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Oncotelic Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 88
2019 60
2018 6
2017 27
2016 27
2015 25
2014 17
2013 3
2012 1
2011 1
2010 0
2009 0
2008 0
2007 0
2006 0
2005 0
Oncotelic Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 370
2021-03-31 94
2020-12-31 88
2020-09-30 89
2020-06-30 95
2020-03-31 85
2019-12-31 60
2019-09-30 75
2019-06-30 65
2019-03-31 7
2018-12-31 6
2018-09-30 6
2018-06-30 6
2018-03-31 27
2017-12-31 27
2017-09-30 27
2017-06-30 27
2017-03-31 27
2016-12-31 27
2016-09-30 27
2016-06-30 27
2016-03-31 27
2015-12-31 25
2015-09-30 27
2015-06-30 27
2015-03-31 21
2014-12-31 17
2014-09-30 21
2014-06-30 17
2014-03-31 9
2013-12-31 3
2013-09-30 3
2013-06-30 2
2013-03-31 2
2012-12-31 2
2012-09-30 1
2012-06-30 1
2012-03-31 1
2011-12-31 2
2011-09-30 1
2011-06-30 1
2011-03-31 1
2010-12-31 0
2010-09-30 0
2010-06-30 0
2010-03-31 0
2009-12-31 0
2009-09-30 0
2009-06-30 0
2009-03-31 0
2008-12-31 0
2008-09-30 0
2008-06-30 0
2008-03-31 0
2007-12-31 0
2007-09-30 0
2007-06-30 0
2007-03-31 0
2006-12-31 0
2006-09-30 0
2006-06-30 0
2006-03-31 0
2005-12-31 0
2005-09-30 0
2005-06-30 0
2005-03-31 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.046B $0.002B
Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting the TGF-beta2 mRNA. Mateon is conducting a Phase 2/3 clinical trial of OT-101 in patients suffering from COVID-19. In addition, the company has initiated a global Phase 4 clinical trial of ArtiShield(TM) in India, Africa, and Latin America for the treatment of COVID-19, with results expected in the 4Q20. ArtiShieldTM received marketing approval from India.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71